Denali Therapeutics (DNLI) Equity Average (2018 - 2025)
Historic Equity Average for Denali Therapeutics (DNLI) over the last 8 years, with Q3 2025 value amounting to $976.6 million.
- Denali Therapeutics' Equity Average fell 2780.57% to $976.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $976.6 million, marking a year-over-year decrease of 2780.57%. This contributed to the annual value of $1.1 billion for FY2024, which is 903.13% up from last year.
- As of Q3 2025, Denali Therapeutics' Equity Average stood at $976.6 million, which was down 2780.57% from $1.1 billion recorded in Q2 2025.
- Denali Therapeutics' 5-year Equity Average high stood at $1.4 billion for Q2 2024, and its period low was $847.9 million during Q3 2022.
- In the last 5 years, Denali Therapeutics' Equity Average had a median value of $1.1 billion in 2025 and averaged $1.1 billion.
- Per our database at Business Quant, Denali Therapeutics' Equity Average surged by 13993.64% in 2021 and then crashed by 2780.57% in 2025.
- Denali Therapeutics' Equity Average (Quarter) stood at $987.3 million in 2021, then dropped by 6.12% to $926.9 million in 2022, then grew by 15.94% to $1.1 billion in 2023, then increased by 18.56% to $1.3 billion in 2024, then decreased by 23.35% to $976.6 million in 2025.
- Its last three reported values are $976.6 million in Q3 2025, $1.1 billion for Q2 2025, and $1.2 billion during Q1 2025.